Allogeneic T Cell Therapies Market Snapshot (2023 to 2033)
According to Future Market Insights, the global allogeneic T cell therapies market was anticipated to reach a valuation of US$ 1.1 billion in the year 2022. Expected to register a CAGR of 9.8% from 2023 to 2033, this market is expected to reach US$ 1.21 billion by 2023, and eventually to US$ 3.08 billion by 2033.
The market for allogeneic T-cell therapy is primarily driven by rising investments in the development of innovative gene therapy-based chemotherapy drugs, rising market accessibility of cell therapy, rising expenditure in T-cell therapies, and technical breakthroughs in diagnostic technologies.
In allogeneic T-cell therapy, healthy people's cells are given to patients to treat a variety of chronic illnesses, including cancer and cardiovascular conditions. The harvested donor cells may be given directly to a patient who shares their genetic makeup or added to a cell bank. Bulk batches of allogenic T-cell treatments are produced using different donor tissues, such as bone marrow. The processes utilized in the scale-up manufacture are comparable to those in the production of protein medicines and other large-scale derived materials. These treatments offer a number of benefits, including being easier to automate, more affordable than autologous therapies, and available as a scalable off-the-shelf product. Thus, these benefits are expected to enhance the global demand for the allogeneic T-cell therapy market from 2023 to 2033.
Increased T-cell research activities and an increase in permissions for GMP-certified institutions to perform cell research and treatments are two factors driving the growth of the allogeneic T-cell therapy market. The demand for novel and improved therapies for neurodegenerative, immunological, as well as myocardial infarctions has resulted in increasing research effort, financing, and desire for allogeneic T-cell therapy.
The key factors influencing the worldwide market for allogeneic T-cell treatment are rising unmet demands for the treatment of long-term illnesses and increased financing for T-cell research. A number of tissue-engineered treatments as well as allogeneic and autologous cell treatments are now being developed by several pharmaceutical companies.
The market for allogeneic T-cell treatment is projected to expand due to the increasing demand for gene and cell therapy as well as the use of induced pluripotent cells instead of embryonic stem cells. The prevalence of cancer as one of the leading killers worldwide has increased public awareness of the disease and the most innovative cell therapies available today.
Also, it is anticipated that the FDA would approve more allogeneic T-cell treatments to treat autoimmune and cardiac illnesses. For instance, in December 2022, the FDA approved BioCardia, Inc.'s IND application to begin a human clinical study using allogeneic human MSC that are Neurokinin-1 receptor positive (NK1R+) to treat patients with ischemic heart failure. The FDA also approved Talaris Therapeutics, Inc.'s IND application for its innovative allogeneic T-cell treatment FCR001 for systemic sclerosis patients in July 2020.
To create innovative allogeneic cell treatments, the major market participants are putting many strategic efforts into practice. For instance, Bristol Myers Squibb and Century Therapeutics entered into a strategic partnership in January 2022 to develop allogeneic medicines produced from iPSCs for solid tumors and hematologic malignancies. Thus, the market for allogeneic T-cell treatment is anticipated to grow throughout the forecast years due to an increase in FDA approvals and strategic moves by key industry participants.
Data Points
Key Statistics
Expected Market Value of Allogenic T-Cell Therapies in 2023
US$ 1.21 billion
Expected Market Value of Allogenic T-Cell Therapies in 2033
US$ 3.08 Billion
Growth Rate (2023 to 2033)
CAGR of 9.8%
Allogeneic T cell therapies depend on a single source of cells for the treatment of various patients. In this, the cells are collected from the donor for the creation of the master cell bank. The Master cell bank is utilized as the source for the creation of cell populace that is further processed as per the demands of the specific treatment.
While the final cell populace is then utilized for the treatment of multiple patients. The allogeneic T cell therapies have various advantages such as the immediate readiness of the cryopreserved batches for the patient therapy, standardization of the CAR-T cell, time for cell modifications, the collaboration of CAR T cells directed against the varied targets, redosing and lower costs using an industrialized procedure.
CAR-T and TCR-T therapies have already revolutionized blood cancer treatment. Researchers Duke-NUS Medical School are examining the capability of turning this approach for the treatment of coronavirus patients.
Scientists also informed that these immunotherapies might also beneficial in the treatment of SARS-CoV-2, the virus resulting in the current outbreak. Various companies are working on cell therapies for coronavirus. AlloVir & Baylor College of Medicine are collaborated to produce an innovative therapy to treat the coronavirus.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Allogeneic T cell therapies Market: Drivers and Restraints
Increasing cases of cancer and a rising variety of patients with failure response to varied treatments are witnessed to boosts the allogeneic T cell therapy market growth globally. Additionally, increasing prevalence of cancer in geriatric & pediatric patients is projected to results in higher demand for an efficient and reliable treatment approach for the improvement of quality of patient’s lives.
Moreover, rising government activities for improving healthcare insurance framework and advancement in research & development activities for allogeneic T cell therapy is fueling the development of the allogeneic T cell therapy market.
Meanwhile, side effects related to the allogeneic T cell therapy may result in cytokine release syndrome & other neurological disorders including coma, seizures, delirium and hallucinations. This factor is witnessed to restrain the allogeneic T cell therapy market growth.
Allogeneic T cell therapies Market: Overview
CD19 target antigens are witnessed to hold the dominant market share owing to the reality that end number of the companies were capable to receive their antigens approved & hence, commercialized them.
Additionally, the diagnostic centers segment held the largest share owing to the rising research and development activities and the utilization of engineered cell therapy in molecular diagnostics. However, the acute lymphoblastic leukaemia has a dominant market share as allogeneic T Cell Therapy offers a therapeutic advantage for the patients who are suffering from the failure of conventional therapy.
Find your sweet spots for generating winning opportunities in this market.
Allogeneic T cell therapies Market: Regional Wise Outlook
Geographically, the allogeneic T cell therapies market is segregated into seven regions viz. Asia Pacific, North America & Latin America, Eastern Europe Western Europe, Japan, & the Middle East and Africa.
North America is expected to dominate the global allogeneic T cell therapies market followed by Europe & Asia Pacific. North America is expected to dominate the global allogeneic T cell therapies market due to the rising venture and research & development activities for the improvement of malignancy treatments in this region.
Meanwhile, Asia Pacific is witnessed to show remarkable developments over the gauge time frame owing to the expanding number of worldwide players teaming up just as assembling contracts for allogeneic T cell treatments with local players in the region.
Allogeneic T cell therapies Market: Key Market Participants
The key participants operating in the global Allogeneic T cell therapies market identified across the value chain include
Autolus.
TrakCel
Tmunity Therapeutics
Bellicum Pharmaceuticals Inc.
Sorrento Therapeutics
Bluebird Inc.
Minerva Biotechnologies Corporation
Kite Pharma
CELGENE CORPORATION
Cellectis
Fortress Biotech.
Promab Biotechnologies
Immune Therapeutics
Ziopharm Oncology Inc
Juno Therapeutics
Novartis AG
Celyad
Eureka Therapeutics Inc.
TILT Biotherapeutics
Poseida Therapeutics Inc.
Meanwhile
The major players are concentrating on the vital merger and securing to upgrade their share in the worldwide allogeneic T cell treatment market. For example, in April 2018, Pfizer, Inc. marked an arrangement with Allogene, to build up an investigational CAR-T cell treatment for rewarding malignant growth.
In January 2019, Novartis declared that they will procure CellforCure with the goal that they can grow their cell and quality treatment. This securing will assist the organization with making their Allogeneic T cell therapies Therapy Kymriah accessible for a huge number of patients worldwide and will likewise assist them with improving their assembling limit of cell and quality treatments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
The report covers exhaust analysis on
Allogeneic T cell therapies Market Segments
Allogeneic T cell therapies Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes
North America (USA, Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, United Kingdom, Spain)
Eastern Europe (Poland, Russia)
Asia Pacific (India, China ASEAN, Australia & New Zealand)
Japan
The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
Allogeneic T cell therapies Market: Segmentation
The global allogeneic T cell therapies market has been segregated based on antigen type, indication, end-user and geography.
